CD274 and non-small cell lung carcinoma: However, as the combination of atezolizumab plus tiragolumab has neither been reported to improve the PFS in the first-line setting in PD-L1 ⩾50% metastatic NSCLC (phase III RCT, SKYSCRAPER-01), PFS, and OS in advanced small cell lung cancer (phase III RCT, SKYSCRAPER-02), the anti-TIGIT enthusiasm has now decreased [69].